Cargando…

EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment

Aberrant expression of ecotropic viral integration site-1 (EVI1(+)) is associated with very poor outcomes in acute myeloid leukemia (AML), mechanisms of which are only partially understood. Using the green fluorescent protein reporter system to monitor EVI1 promoter activity, we demonstrated that Ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Masamoto, Yosuke, Chiba, Akira, Mizuno, Hideaki, Hino, Toshiya, Hayashida, Hiroki, Sato, Tomohiko, Bando, Masashige, Shirahige, Katsuhiko, Kurokawa, Mineo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139867/
https://www.ncbi.nlm.nih.gov/pubmed/36269819
http://dx.doi.org/10.1182/bloodadvances.2022008018
_version_ 1785033041212604416
author Masamoto, Yosuke
Chiba, Akira
Mizuno, Hideaki
Hino, Toshiya
Hayashida, Hiroki
Sato, Tomohiko
Bando, Masashige
Shirahige, Katsuhiko
Kurokawa, Mineo
author_facet Masamoto, Yosuke
Chiba, Akira
Mizuno, Hideaki
Hino, Toshiya
Hayashida, Hiroki
Sato, Tomohiko
Bando, Masashige
Shirahige, Katsuhiko
Kurokawa, Mineo
author_sort Masamoto, Yosuke
collection PubMed
description Aberrant expression of ecotropic viral integration site-1 (EVI1(+)) is associated with very poor outcomes in acute myeloid leukemia (AML), mechanisms of which are only partially understood. Using the green fluorescent protein reporter system to monitor EVI1 promoter activity, we demonstrated that Evi1(high) KMT2A-MLLT1–transformed AML cells possess distinct features from Evi1(low) cells: the potential for aggressive disease independent of stem cell activity and resistance to cytotoxic chemotherapy, along with the consistent gene expression profiles. RNA sequencing and chromatin immunoprecipitation sequencing in EVI1-transformed AML cells and normal hematopoietic cells combined with functional screening by cell proliferation–related short hairpin RNAs revealed that the erythroblast transformation–specific transcription factor ERG (E26 transformation-specific [ETS]-related gene) and cyclin D1 were downstream targets and therapeutic vulnerabilities of EVI1(+) AML. Silencing Erg in murine EVI1(+) AML models severely impaired cell proliferation, chemoresistance, and leukemogenic capacity. Cyclin D1 is also requisite for efficient EVI1-AML development, associated with gene expression profiles related to chemokine production and interferon signature, and T- and natural killer–cell exhaustion phenotype, depending on the interferon gamma (IFN-γ)/STAT1 pathway but not on CDK4/CDK6. Inhibiting the IFN-γ/STAT1 pathway alleviated immune exhaustion and impaired EVI1-AML development. Overexpression of EVI1 and cyclin D1 was associated with IFN-γ signature and increased expression of chemokines, with increased exhaustion molecules in T cells also in human AML data sets. These data collectively suggest that ERG and cyclin D1 play pivotal roles in the biology of EVI1(+) AML, where ERG contributes to aggressive disease nature and chemoresistance, and cyclin D1 leads to IFN-γ signature and exhausted T-cell phenotypes, which could potentially be targeted.
format Online
Article
Text
id pubmed-10139867
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-101398672023-04-29 EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment Masamoto, Yosuke Chiba, Akira Mizuno, Hideaki Hino, Toshiya Hayashida, Hiroki Sato, Tomohiko Bando, Masashige Shirahige, Katsuhiko Kurokawa, Mineo Blood Adv Myeloid Neoplasia Aberrant expression of ecotropic viral integration site-1 (EVI1(+)) is associated with very poor outcomes in acute myeloid leukemia (AML), mechanisms of which are only partially understood. Using the green fluorescent protein reporter system to monitor EVI1 promoter activity, we demonstrated that Evi1(high) KMT2A-MLLT1–transformed AML cells possess distinct features from Evi1(low) cells: the potential for aggressive disease independent of stem cell activity and resistance to cytotoxic chemotherapy, along with the consistent gene expression profiles. RNA sequencing and chromatin immunoprecipitation sequencing in EVI1-transformed AML cells and normal hematopoietic cells combined with functional screening by cell proliferation–related short hairpin RNAs revealed that the erythroblast transformation–specific transcription factor ERG (E26 transformation-specific [ETS]-related gene) and cyclin D1 were downstream targets and therapeutic vulnerabilities of EVI1(+) AML. Silencing Erg in murine EVI1(+) AML models severely impaired cell proliferation, chemoresistance, and leukemogenic capacity. Cyclin D1 is also requisite for efficient EVI1-AML development, associated with gene expression profiles related to chemokine production and interferon signature, and T- and natural killer–cell exhaustion phenotype, depending on the interferon gamma (IFN-γ)/STAT1 pathway but not on CDK4/CDK6. Inhibiting the IFN-γ/STAT1 pathway alleviated immune exhaustion and impaired EVI1-AML development. Overexpression of EVI1 and cyclin D1 was associated with IFN-γ signature and increased expression of chemokines, with increased exhaustion molecules in T cells also in human AML data sets. These data collectively suggest that ERG and cyclin D1 play pivotal roles in the biology of EVI1(+) AML, where ERG contributes to aggressive disease nature and chemoresistance, and cyclin D1 leads to IFN-γ signature and exhausted T-cell phenotypes, which could potentially be targeted. The American Society of Hematology 2022-10-27 /pmc/articles/PMC10139867/ /pubmed/36269819 http://dx.doi.org/10.1182/bloodadvances.2022008018 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Myeloid Neoplasia
Masamoto, Yosuke
Chiba, Akira
Mizuno, Hideaki
Hino, Toshiya
Hayashida, Hiroki
Sato, Tomohiko
Bando, Masashige
Shirahige, Katsuhiko
Kurokawa, Mineo
EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment
title EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment
title_full EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment
title_fullStr EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment
title_full_unstemmed EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment
title_short EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment
title_sort evi1 exerts distinct roles in aml via erg and cyclin d1 promoting a chemoresistant and immune-suppressive environment
topic Myeloid Neoplasia
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139867/
https://www.ncbi.nlm.nih.gov/pubmed/36269819
http://dx.doi.org/10.1182/bloodadvances.2022008018
work_keys_str_mv AT masamotoyosuke evi1exertsdistinctrolesinamlviaergandcyclind1promotingachemoresistantandimmunesuppressiveenvironment
AT chibaakira evi1exertsdistinctrolesinamlviaergandcyclind1promotingachemoresistantandimmunesuppressiveenvironment
AT mizunohideaki evi1exertsdistinctrolesinamlviaergandcyclind1promotingachemoresistantandimmunesuppressiveenvironment
AT hinotoshiya evi1exertsdistinctrolesinamlviaergandcyclind1promotingachemoresistantandimmunesuppressiveenvironment
AT hayashidahiroki evi1exertsdistinctrolesinamlviaergandcyclind1promotingachemoresistantandimmunesuppressiveenvironment
AT satotomohiko evi1exertsdistinctrolesinamlviaergandcyclind1promotingachemoresistantandimmunesuppressiveenvironment
AT bandomasashige evi1exertsdistinctrolesinamlviaergandcyclind1promotingachemoresistantandimmunesuppressiveenvironment
AT shirahigekatsuhiko evi1exertsdistinctrolesinamlviaergandcyclind1promotingachemoresistantandimmunesuppressiveenvironment
AT kurokawamineo evi1exertsdistinctrolesinamlviaergandcyclind1promotingachemoresistantandimmunesuppressiveenvironment